Alkermes Reports $241.7 Million Net Income for Fiscal Year 2025, Completes Acquisition of Avadel Pharmaceuticals

Alkermes plc reported a net income of $241.7 million for the fiscal year ending December 31, 2025, a decrease from $372.1 million in 2024. The decline in profitability was attributed to a rise in total expenses by $84.9 million and a drop of $182.8 million in manufacturing and royalty revenues, which were partially offset by a $101.1 million increase in product sales. The company’s total revenues for 2025 were $1.48 billion, compared to $1.56 billion in 2024. The increase in product sales was primarily driven by a 19% rise in units sold for LYBALVI and a 3% price increase for LYBALVI, ARISTADA, and ARISTADA INITIO, despite decreases in sales for VIVITROL and ARISTADA.

In a significant strategic move, Alkermes completed the acquisition of Avadel Pharmaceuticals on February 12, 2026, for $21.00 per share, which included a contingent value right of $1.50 per share based on future milestones. This acquisition added LUMRYZ, a treatment for narcolepsy, to Alkermes' portfolio, which is expected to enhance revenue streams. The company also sold its Athlone Facility to Novo Nordisk in May 2024, which concluded its manufacturing obligations for certain legacy products, impacting its cost structure and revenue generation.

Operationally, Alkermes reported a workforce of approximately 2,050 employees as of February 20, 2026, with a voluntary attrition rate of 7.0%, below industry benchmarks. The company’s sales force for VIVITROL consisted of about 105 individuals, while the sales force for ARISTADA, ARISTADA INITIO, and LYBALVI totaled approximately 435. The company’s sales strategy focuses on direct engagement with healthcare providers and leveraging its proprietary technologies to maintain a competitive edge in the biopharmaceutical market.

Looking ahead, Alkermes anticipates continued growth in product sales, particularly from its proprietary products and the newly acquired LUMRYZ. However, the company faces challenges, including increased competition from generic products and the need to navigate complex regulatory environments. The company’s financial outlook remains cautious, with expectations of increased research and development expenditures as it advances its pipeline, particularly for alixorexton, which is set to enter phase 3 clinical trials in 2026. Alkermes is also focused on managing its debt obligations following the acquisition, which could impact its financial flexibility in the near term.